查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423556

2030 年Gabapentin市场预测：按产品类型、给药途径、购买型态、应用、最终用户和地区进行的全球分析

Gabapentin Market Forecasts to 2030 - Global Analysis By Product (Tablet, Capsule and Other Products), Type (Generic, Branded and Other Types), Route of Administration, Mode of Purchase, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2023年全球Gabapentin市场规模为21.7152亿美元，预计到2030年将达到35.6761亿美元，预测期内复合年增长率为7.4%。

Gabapentin是一种模仿神经传导物质γ-胺基丁酸（GABA）的药物，主要用作抗惊厥药物和缓解神经病变疼痛。它经美国食品药物管理局(FDA)核准，用于治疗多种疾病，包括癫痫、带状疱疹后遗症神经痛和不宁腿症候群。由于其在治疗神经系统疾病和慢性疼痛方面的多功能性，它已成为现代医学的宝贵资产。

报告称，Gabapentin在2020年美国处方药中排名第6。 2020年，美国将开出5,700万张处方笺。

提高意识

医疗保健专业人员和患者越来越了解该药物在治疗各种神经系统疾病和神经性疼痛方面的有效性。GabapentinGabapentin。此外，以患者为中心的医疗保健正在不断发展并鼓励明智的决策，从而成为推动该市场的关键因素。

误用和滥用

Gabapentin的滥用包括服用超过处方量、未经处方笺使用以及与其他物质一起使用以增强所需效果。Gabapentin滥用可引起多种副作用，包括头晕、镇静、失去协调性、视力模糊和认知障碍。此外，长期误用或滥用Gabapentin后突然停药可能会导致焦虑、失眠和烦躁等戒断症状，这将严重阻碍该市场的扩张。

扩大远端医疗服务

远端医疗服务的扩展将有助于医疗保健，并对Gabapentin的获取产生积极影响，使需要治疗神经系统疾病和神经性疼痛的患者能够轻鬆使用该药物。远端医疗允许医疗保健提供者远端进行咨询、开药和监控患者状况。此外，远端医疗使医疗保健专业人员能够远端监控患者、快速解决问题并优化药物管理，这正在推动这个市场。

副作用和耐受性

副作用的普遍存在给医疗保健提供者带来了平衡Gabapentin的治疗益处及其潜在缺点的挑战。患者特定因素，例如年龄、潜在疾病和合併用药，可能会影响副作用的可能性和严重程度。此外，副作用的存在阻碍了市场成长，因为它们可能需要额外的医疗干预措施，从而增加医疗成本和资源利用率。

COVID-19 的影响

COVID-19大流行对Gabapentin市场产生了一些负面影响。供应链中断、封锁措施和医疗保健优先事项的转变共同为Gabapentin的生产、分销和消费带来了挑战。经济不确定性和医疗保健系统的财务压力可能会推动成本降低并影响Gabapentin的承受能力。此外，就诊医疗机构的患者数量减少可能会导致新处方和重复处方的减少，从而影响整体市场需求。

胶囊细分市场预计将在预测期内成为最大的细分市场

据估计，胶囊占最大份额。这些是治疗神经系统疾病和神经性疼痛的广泛处方药物，可有效治疗带状疱疹后遗症神经痛神经病变和糖尿病神经病变等疾病。研究和开发计划、监管核准和策略联盟等因素影响市场动态。此外，对创新、安全性和可近性的关注仍然是更广泛的製药市场的重要贡献者，并推动该领域的成长。

预计肠外药物领域在预测期内复合年增长率最高

预计肠外用药在预测期内的复合年增长率最高，因为它具有明显的优势，特别是在口服摄入困难的情况下，例如噁心、呕吐和吞嚥困难的患者。这种给药方法提高了治疗依从性，并确保患者准确地接受处方剂量。此外，Gabapentin的肠胃外製剂为需要快速起效和精确剂量控制的患者提供了有效的替代方案，推动了该领域的成长。

占比最高的地区

由于北美在治疗神经系统疾病和神经性疼痛的药物市场中占有重要地位，因此在预测期内获得了最大的市场占有率。辉瑞公司、梯瓦製药有限公司、Glenmark 製药有限公司和 Cipla USA Inc. 等主要市场是治疗癫痫、带状疱疹后遗症神经痛和糖尿病神经病变等疾病的核心。此外，美国食品药物管理局(FDA) 和加拿大卫生署等法律规范机构确保遵守安全标准并在该地区有效分销。

复合年增长率最高的地区：

由于欧洲在控制癫痫、带状疱疹后遗症神经痛和糖尿病神经病变等疾病方面的有效性，预计在预测期内将显示出最高的复合年增长率。製药公司从事製造和行销活动，以满足对Gabapentin不断增长的需求，为欧洲与神经系统疾病作斗争的人们提供有效的解决方案。此外，神经系统疾病盛行率上升、人口老化以及慢性疼痛管理意识的提高等因素正在推动该地区的扩张。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球Gabapentin市场：副产品

  • 锭剂
  • 胶囊
  • 其他产品

第六章全球Gabapentin市场：按类型

  • 非专利的
  • 品牌
  • 其他类型

第七章全球Gabapentin市场：依给药途径

  • 胃肠外的
  • 口服
  • 静脉
  • 其他给药途径

第八章全球Gabapentin市场：依采购型态

  • 处方笺
  • 店面销售(OTC)
  • 零售

第九章全球Gabapentin市场：依应用分类

  • 神经性疼痛
  • 癫痫
  • 不宁腿症候群
  • 其他用途

第10章全球Gabapentin市场：依最终用户分类

  • 网路药房
  • 医院药房
  • 其他最终用户

第十一章全球Gabapentin市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司简介

  • Amneal Pharmaceuticals LLC.
  • Intas Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Marksans Pharma
  • Novartis AG
  • Alkem Labs
  • Jiangsu Nhwa Pharmaceutical Co., Ltd
  • Aurobindo Pharma
  • Apotex Inc
  • Viatris Inc
  • Arbor Pharmaceuticals, LLC
  • Pfizer Inc
  • Teva Pharmaceuticals Ltd
  • Glenmark Pharmaceuticals Limited
  • Ascend Laboratories, LLC
  • Cipla USA, Inc.
Product Code: SMRC24790

According to Stratistics MRC, the Global Gabapentin Market is accounted for $2,171.52 million in 2023 and is expected to reach $3,567.61 million by 2030 growing at a CAGR of 7.4% during the forecast period. Gabapentin is a pharmaceutical compound used primarily as an anticonvulsant and to alleviate neuropathic pain which mimic the neurotransmitter gamma-aminobutyric acid (GABA). It is approved by the U.S. Food and Drug Administration (FDA), and is employed in the treatment of various medical conditions, including epilepsy, postherpetic neuralgia, and restless legs syndrome. The drug's versatility in addressing neurological disorders and chronic pain has made it a valuable asset in modern medicine.

According to a report, gabapentin ranks sixth in prescribed medication in the United States in 2020. Nearly, 57 million prescriptions were written for the drug in the country in 2020.

Market Dynamics:

Driver:

Increase in awareness

Healthcare professionals and patients are becoming more informed about the drug's efficacy in managing various neurological disorders and neuropathic pain conditions. Physicians are increasingly prescribing Gabapentin based on a deeper understanding of its mechanisms of action and the diverse range of conditions it can effectively address. In addition, the evolving landscape of patient-centered healthcare encourages informed decision-making, making awareness a crucial factor in driving this market.

Restraint:

Misuse and abuse

Gabapentin misuse can involve taking higher doses than prescribed, using it without a prescription, or combining it with other substances to intensify the desired effects. Abuse of gabapentin can result in various adverse effects, including dizziness, sedation, impaired coordination, blurred vision, and cognitive difficulties. Furthermore, abrupt discontinuation of gabapentin after prolonged misuse or abuse can result in withdrawal symptoms such as anxiety, insomnia, and restlessness, significantly hampering this market expansion.

Opportunity:

Telehealth expansion

The expansion of telehealth services serves healthcare and positively impacts the accessibility of this medication by transforming easy delivery for individuals requiring gabapentin for neurological disorders and neuropathic pain. Telehealth allows healthcare providers to conduct remote consultations, prescribe medications, and monitor patients' conditions from a distance. Further, telehealth enables healthcare professionals to monitor patients remotely, address concerns promptly, and optimize medication management, which is propelling this market

Threat:

Side effects and tolerance

The prevalence of side effects poses challenges for healthcare providers in balancing the therapeutic benefits of Gabapentin with its potential drawbacks. Patient-specific factors, such as age, underlying health conditions, and concurrent medications, can influence the likelihood and severity of side effects. Moreover, the presence of side effects may necessitate additional medical interventions, contributing to healthcare costs and resource utilization and thereby hindering market growth.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the Gabapentin market. Supply chain disruptions, lockdown measures, and shifts in healthcare priorities have collectively contributed to challenges in the production, distribution, and consumption of gabapentin. Economic uncertainties and financial strains on healthcare systems have prompted cost-cutting measures, potentially influencing the affordability of Gabapentin. Moreover, reduced patient visits to healthcare providers may have led to a decline in new prescriptions and refills, affecting overall market demand.

The capsule segment is expected to be the largest during the forecast period

The capsule segment is estimated to hold the largest share. These are pharmaceutical products widely prescribed for neurological disorders and neuropathic pain that are efficient in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Factors such as research and development initiatives, regulatory approvals, and strategic collaborations influence market dynamics. Furthermore, a focus on innovation, safety, and accessibility continues to be a vital contributor to the broader pharmaceutical market, driving this segment's growth.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to have highest CAGR during the forecast period due to distinct advantages, particularly in situations where oral intake may be challenging, such as for patients experiencing nausea, vomiting, or those with difficulty swallowing. This mode of delivery enhances treatment compliance and ensures patients receive the prescribed dosage accurately. Additionally, for individuals requiring rapid onset of action or precise dosage control, parenteral formulations of gabapentin provide an effective alternative, boosting this segment's expansion.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to its significant presence in the pharmaceutical landscape, addressing neurological disorders and neuropathic pain. Key markets such as Pfizer Inc., Teva Pharmaceuticals Ltd., Glenmark Pharmaceuticals Limited, and Cipla USA Inc. have become cornerstones in the management of conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Furthermore, regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA) and Health Canada ensures compliance with safety standards and effective distribution in this region.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to its efficacy in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Pharmaceutical companies engage in manufacturing and marketing activities to meet the increasing demand for Gabapentin, aiming to provide effective solutions for individuals grappling with neurological conditions in Europe. In addition, factors such as the rising prevalence of neurological disorders, an aging population, and an increased awareness of chronic pain management are boosting this region's expansion.

Key players in the market

Some of the key players in the Gabapentin Market include Amneal Pharmaceuticals LLC., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd, Marksans Pharma, Novartis AG, Alkem Labs, Jiangsu Nhwa Pharmaceutical Co., Ltd, Aurobindo Pharma, Apotex Inc, Viatris Inc, Arbor Pharmaceuticals, LLC, Pfizer Inc, Teva Pharmaceuticals Ltd, Glenmark Pharmaceuticals Limited, Ascend Laboratories, LLC and Cipla USA, Inc.

Key Developments:

In December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

In October 2023, Zydus Lifesciences Company and Sun Pharmaceutical Industries Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India.

In January 2023, Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment in equity value.

Products Covered:

  • Tablet
  • Capsule
  • Other Products

Types Covered:

  • Generic
  • Branded
  • Other Types

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Intravenous
  • Other Route of Administrations

Mode of Purchase Covered:

  • Prescription
  • Over the Counter(OTC)
  • Retail

Applications Covered:

  • Neuropathic Pain
  • Epilepsy
  • Restless Legs Syndrome
  • Other Applications

End Users Covered:

  • Online Pharmacies
  • Hospital Pharmacy
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Gabapentin Market, By Product

  • 5.1 Introduction
  • 5.2 Tablet
  • 5.3 Capsule
  • 5.4 Other Products

6 Global Gabapentin Market, By Type

  • 6.1 Introduction
  • 6.2 Generic
  • 6.3 Branded
  • 6.4 Other Types

7 Global Gabapentin Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral
  • 7.4 Intravenous
  • 7.5 Other Route of Administrations

8 Global Gabapentin Market, By Mode of Purchase

  • 8.1 Introduction
  • 8.2 Prescription
  • 8.3 Over the Counter (OTC)
  • 8.4 Retail

9 Global Gabapentin Market, By Application

  • 9.1 Introduction
  • 9.2 Neuropathic Pain
  • 9.3 Epilepsy
  • 9.4 Restless Legs Syndrome
  • 9.5 Other Applications

10 Global Gabapentin Market, By End User

  • 10.1 Introduction
  • 10.2 Online Pharmacies
  • 10.3 Hospital Pharmacy
  • 10.4 Other End Users

11 Global Gabapentin Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Amneal Pharmaceuticals LLC.
  • 13.2 Intas Pharmaceuticals Ltd.
  • 13.3 Sun Pharmaceutical Industries Ltd
  • 13.4 Marksans Pharma
  • 13.5 Novartis AG
  • 13.6 Alkem Labs
  • 13.7 Jiangsu Nhwa Pharmaceutical Co., Ltd
  • 13.8 Aurobindo Pharma
  • 13.9 Apotex Inc
  • 13.10 Viatris Inc
  • 13.11 Arbor Pharmaceuticals, LLC
  • 13.12 Pfizer Inc
  • 13.13 Teva Pharmaceuticals Ltd
  • 13.14 Glenmark Pharmaceuticals Limited
  • 13.15 Ascend Laboratories, LLC
  • 13.16 Cipla USA, Inc.

List of Tables

  • Table 1 Global Gabapentin Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Gabapentin Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 4 Global Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
  • Table 5 Global Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 6 Global Gabapentin Market Outlook, By Type (2021-2030) ($MN)
  • Table 7 Global Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
  • Table 8 Global Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
  • Table 9 Global Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 10 Global Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 11 Global Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 12 Global Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 13 Global Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 14 Global Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 15 Global Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
  • Table 16 Global Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
  • Table 17 Global Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
  • Table 18 Global Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
  • Table 19 Global Gabapentin Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
  • Table 21 Global Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 22 Global Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
  • Table 23 Global Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 Global Gabapentin Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 26 Global Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 27 Global Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 28 North America Gabapentin Market Outlook, By Country (2021-2030) ($MN)
  • Table 29 North America Gabapentin Market Outlook, By Product (2021-2030) ($MN)
  • Table 30 North America Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 31 North America Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
  • Table 32 North America Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 33 North America Gabapentin Market Outlook, By Type (2021-2030) ($MN)
  • Table 34 North America Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
  • Table 35 North America Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
  • Table 36 North America Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 37 North America Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 38 North America Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 39 North America Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 40 North America Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 41 North America Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 42 North America Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
  • Table 43 North America Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
  • Table 44 North America Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
  • Table 45 North America Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
  • Table 46 North America Gabapentin Market Outlook, By Application (2021-2030) ($MN)
  • Table 47 North America Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
  • Table 48 North America Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 49 North America Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
  • Table 50 North America Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 51 North America Gabapentin Market Outlook, By End User (2021-2030) ($MN)
  • Table 52 North America Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 53 North America Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 54 North America Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 55 Europe Gabapentin Market Outlook, By Country (2021-2030) ($MN)
  • Table 56 Europe Gabapentin Market Outlook, By Product (2021-2030) ($MN)
  • Table 57 Europe Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 58 Europe Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
  • Table 59 Europe Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 60 Europe Gabapentin Market Outlook, By Type (2021-2030) ($MN)
  • Table 61 Europe Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
  • Table 62 Europe Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
  • Table 63 Europe Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 64 Europe Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 65 Europe Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 66 Europe Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 67 Europe Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 68 Europe Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 69 Europe Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
  • Table 70 Europe Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
  • Table 71 Europe Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
  • Table 72 Europe Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
  • Table 73 Europe Gabapentin Market Outlook, By Application (2021-2030) ($MN)
  • Table 74 Europe Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
  • Table 75 Europe Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 76 Europe Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
  • Table 77 Europe Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 78 Europe Gabapentin Market Outlook, By End User (2021-2030) ($MN)
  • Table 79 Europe Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 80 Europe Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 81 Europe Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 82 Asia Pacific Gabapentin Market Outlook, By Country (2021-2030) ($MN)
  • Table 83 Asia Pacific Gabapentin Market Outlook, By Product (2021-2030) ($MN)
  • Table 84 Asia Pacific Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 85 Asia Pacific Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
  • Table 86 Asia Pacific Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 87 Asia Pacific Gabapentin Market Outlook, By Type (2021-2030) ($MN)
  • Table 88 Asia Pacific Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
  • Table 89 Asia Pacific Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
  • Table 90 Asia Pacific Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 91 Asia Pacific Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 92 Asia Pacific Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 93 Asia Pacific Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 94 Asia Pacific Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 95 Asia Pacific Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 96 Asia Pacific Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
  • Table 97 Asia Pacific Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
  • Table 98 Asia Pacific Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
  • Table 99 Asia Pacific Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
  • Table 100 Asia Pacific Gabapentin Market Outlook, By Application (2021-2030) ($MN)
  • Table 101 Asia Pacific Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
  • Table 102 Asia Pacific Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 103 Asia Pacific Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
  • Table 104 Asia Pacific Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 105 Asia Pacific Gabapentin Market Outlook, By End User (2021-2030) ($MN)
  • Table 106 Asia Pacific Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 107 Asia Pacific Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 108 Asia Pacific Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 109 South America Gabapentin Market Outlook, By Country (2021-2030) ($MN)
  • Table 110 South America Gabapentin Market Outlook, By Product (2021-2030) ($MN)
  • Table 111 South America Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 112 South America Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
  • Table 113 South America Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 114 South America Gabapentin Market Outlook, By Type (2021-2030) ($MN)
  • Table 115 South America Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
  • Table 116 South America Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
  • Table 117 South America Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 118 South America Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 119 South America Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 120 South America Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 121 South America Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 122 South America Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 123 South America Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
  • Table 124 South America Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
  • Table 125 South America Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
  • Table 126 South America Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
  • Table 127 South America Gabapentin Market Outlook, By Application (2021-2030) ($MN)
  • Table 128 South America Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
  • Table 129 South America Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 130 South America Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
  • Table 131 South America Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 132 South America Gabapentin Market Outlook, By End User (2021-2030) ($MN)
  • Table 133 South America Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 134 South America Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 135 South America Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 136 Middle East & Africa Gabapentin Market Outlook, By Country (2021-2030) ($MN)
  • Table 137 Middle East & Africa Gabapentin Market Outlook, By Product (2021-2030) ($MN)
  • Table 138 Middle East & Africa Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 139 Middle East & Africa Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
  • Table 140 Middle East & Africa Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 141 Middle East & Africa Gabapentin Market Outlook, By Type (2021-2030) ($MN)
  • Table 142 Middle East & Africa Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
  • Table 143 Middle East & Africa Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
  • Table 144 Middle East & Africa Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 145 Middle East & Africa Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 146 Middle East & Africa Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 147 Middle East & Africa Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 148 Middle East & Africa Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 149 Middle East & Africa Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 150 Middle East & Africa Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
  • Table 151 Middle East & Africa Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
  • Table 152 Middle East & Africa Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
  • Table 153 Middle East & Africa Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
  • Table 154 Middle East & Africa Gabapentin Market Outlook, By Application (2021-2030) ($MN)
  • Table 155 Middle East & Africa Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
  • Table 156 Middle East & Africa Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 157 Middle East & Africa Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
  • Table 158 Middle East & Africa Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 159 Middle East & Africa Gabapentin Market Outlook, By End User (2021-2030) ($MN)
  • Table 160 Middle East & Africa Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 161 Middle East & Africa Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 162 Middle East & Africa Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)